New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2013
09:35 EDTTWTR, AAPL, MA, GILD, TSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA GILD MA TWTR GOOG
News For AAPL;TSLA;MA;TWTR;GILD From The Last 14 Days
Check below for free stories on AAPL;TSLA;MA;TWTR;GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
April 8, 2014
07:12 EDTTSLATesla Model S demand may have plateaued in U.S., says Barclays
Subscribe for More Information
06:47 EDTTSLATesla announces launch of leasing for business owners
Subscribe for More Information
06:24 EDTAAPLApple may develop baseband chpis for iPhones inhouse, DigiTimes says
Subscribe for More Information
06:20 EDTAAPLApple may release iWatch in Q3, DigiTimes reports
Subscribe for More Information
06:19 EDTTWTRTwitter initiated with a Buy at Janney Capital
Subscribe for More Information
06:07 EDTAAPLMicrosoft investing in 'invisible user interface' technology, WSJ reports
Subscribe for More Information
April 7, 2014
16:01 EDTAAPL, TSLAOptions Update; April 7, 2014
Subscribe for More Information
14:06 EDTAAPLApple slips to lows of the day, levels to watch
Shares were last at $522.56, just off the session low. At current price, next support is at $517.35. Resistance is at $527.67.
12:11 EDTTWTRTwitter acquires Cover, terms not disclosed
Subscribe for More Information
11:42 EDTTSLAStocks with call strike movement; DDD TSLA
3D Systems (DDD) August 65 call option implied volatility increased 4% to 50, Tesla (TSLA) September 250 call option implied volatility increased 2% to 55 according to IVolatility.
09:34 EDTAAPL, TSLA, GILDActive equity options trading on open
Subscribe for More Information
08:45 EDTAAPLInvenSense price target raised to $27 from $20 at Pacific Crest
Subscribe for More Information
08:31 EDTGILDGilead announecs FDA priority review designation for Ledipasvir/Sofosbuvir
Gilead Sciences announced that the U.S. Food and Drug Administration has granted priority review to the company’s New Drug Application for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead filed the NDA for LDV/SOF on February 10, and the FDA has set a target action date under the Prescription Drug User Fee Act of October 10. The FDA has also assigned LDV/SOF a Breakthrough Therapy designation.
07:51 EDTAAPLApple sent iTV panel samples from Korean display maker, Korea Herald says
Subscribe for More Information
07:46 EDTTSLATesla potential weak results priced into shares, says RW Baird
Subscribe for More Information
07:37 EDTAAPLApple considered dumping long-time ad agency, WSJ reports
Subscribe for More Information
07:16 EDTAAPL, MARetailers muscle into competitive mobile payment market, Reuters says
Subscribe for More Information
06:49 EDTTWTRWeibo looking to raise over $380M in IPO, NY Times says
SINA's (SINA) Weibo hopes to raise more than $380M in its upcoming IPO and price its shares at $17-$19, Weibo said in its prospectus, according to The New York Times. Known as a "microblog," Weibo has been compared to Twitter (TWTR). Reference Link
06:36 EDTAAPLApple's sales force worried about iPhone outlook, Re/code reports
Apple's (AAPL) sales force has been worried about weakness in the iPhone's market share, amid strong competition from Google's (GOOG) Android operating system, a document presented in a court case showed, Re/code reported on Friday. According to the internal Apple document, the only portions of the smartphone market showing growth were large devices costing more than $300 or devices that cost less than $300, the website stated. Reference Link
April 6, 2014
17:48 EDTAAPLGoogle set to announce Android TV, The Verge says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use